Latest Ratios: P/E Ratio -22.3x · EV/EBITDA N/A · ROE -11.9%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $3.1B | $4.1B | $1.4B | $1.5B | — | — | — |
| Enterprise Value | $2.3B | $3.3B | $1.3B | $1.4B | — | — | — |
| P/E Ratio → | -22.27 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 2.09 | 2.72 | 1.65 | 3.31 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -11.9% | -11.9% | -18.6% | -53.1% | — | — | — |
| ROA | -11.4% | -11.4% | -17.7% | -30.9% | -49.1% | -53.4% | -41.1% |
| ROIC | -30.3% | -30.3% | -23.1% | -82.2% | — | — | — |
| ROCE | -24.1% | -24.1% | -23.9% | -37.9% | -56.1% | -54.6% | -44.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.52 | -0.19 | -0.27 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -7.67 | — | -308.58 | — |
Net cash position: cash ($800M) exceeds total debt ($6M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 24.81 | 24.81 | 24.74 | 19.14 | 7.16 | 12.62 | 12.64 |
| Quick Ratio | 24.81 | 24.81 | 24.74 | 19.14 | 7.16 | 12.62 | 12.64 |
| Cash Ratio | 22.85 | 22.85 | 24.53 | 18.89 | 6.98 | 12.39 | 12.32 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $59M | $53M | $37M | $37M | $37M | $37M |
Clinical trial execution failure
As reported in financial statements, the company trades at a price-to-book ratio of 1.94, a valuation that appears to be driven by the scarcity of independent oral GLP-1 assets rather than traditional earnings multiples, which remain negative given the firm's pre-revenue clinical-stage status.
The lack of meaningful P/E or EV/EBITDA metrics reflects the market's focus on the potential peak sales of the metabolic pipeline rather than current operational performance. Investors should monitor whether this premium holds as competitive data from larger, better-capitalized peers begins to set a higher efficacy bar for the entire oral small molecule class.
Based on reported figures, the company's ROIC has fluctuated between -9.8% and -6.1% over the last ten quarters, illustrating the inherent difficulty of generating positive returns on invested capital while the firm remains in a heavy, non-revenue-generating research and development phase.
The persistent negative ROIC is a structural feature of the business model, where capital is deployed into long-dated clinical trials rather than income-generating assets. This trend warrants further investigation into whether the company can achieve a pivot toward positive returns once the lead metabolic asset reaches commercialization or licensing milestones.
According to recent SEC filings, the company maintains a current ratio of 26.16 as of 2026Q1, a figure that suggests a highly liquid position capable of sustaining the firm's aggressive clinical trial schedule without immediate reliance on external financing or dilutive capital raises.
This liquidity profile is exceptionally strong for a clinical-stage biotech, providing management with the operational flexibility to advance the metabolic pipeline independently. However, the rapid consumption of this cash buffer suggests that the current liquidity position is a temporary state that will inevitably tighten as Phase 3 trial costs escalate.
As indicated by the peer comparison data, Structure Therapeutics' P/B ratio of 1.94 sits significantly below the high-multiple valuations seen in peers like Revolution Medicine, suggesting that the market may be discounting the company's platform relative to firms with more advanced or diversified clinical portfolios.
The valuation gap relative to peers like VKTX may indicate that investors are waiting for more definitive clinical proof-of-concept data before assigning a higher scarcity premium. This divergence warrants further investigation into whether the market is underestimating the potential of the company's biased signaling platform compared to the more traditional approaches of its competitors.
The most commonly misapplied metric for this business model is the P/E ratio, which obscures the reality that the company's net losses are essentially capitalized R&D investments rather than operational failures, rendering standard valuation multiples largely irrelevant for assessing the firm's true long-term intrinsic value.
Investors should instead focus on cash runway and clinical milestone progress, as these are the primary drivers of value in a pre-revenue biotech firm. Relying on P/E or EBITDA-based valuation for a company in this stage may lead to an incorrect assessment of the firm's financial health and growth potential.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GPCR stock.
Structure Therapeutics Inc.'s current P/E ratio is -22.3x. This places it at the 50th percentile of its historical range.
Structure Therapeutics Inc.'s return on equity (ROE) is -11.9%. The historical average is -27.8%.
Based on historical data, Structure Therapeutics Inc. is trading at a P/E of -22.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.